作者
Bandana Singh, Adam Kanack, Antonios Bayas, Gemlyn George, Mouhamed Yazan Abou Abou-Ismail, Mindy Kohlhagen, Monika Christ, Markus Naumann, Karen A Moser, Kristi J Smock, Alison Grazioli, David L Murray, Anand Padmanabhan
发表日期
2021/11/23
期刊
Blood
卷号
138
期号
Supplement 1
页码范围
3220-3220
出版商
American Society of Hematology
简介
Background: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26. COV2. S (Janssen Johnson & Johnson) vaccines against COVID-19 have been associated with thrombotic thrombocytopenic reactions referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by the presence of platelet-activating, anti-PF4 antibodies. While VITT shares key clinical features with a similar but separate entity, Heparin-induced thrombocytopenia (HIT), there appear to be important differences: 1) VITT patients have extremely high thrombosis rates and are very strongly positive in PF4-polyanion ELISAs, and 2) Many patients with VITT frequently present with refractoriness to therapy or have disease recurrence that suggests distinct antibody characteristics due to a strong autoimmune anti-PF4 response.
Aims: The goal of this study was to characterize anti-PF4 antibodies in VITT.
Methods: Five VITT patients were …
学术搜索中的文章
B Singh, A Kanack, A Bayas, G George… - Blood, 2021